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The aim of this study was to obtain preliminary exhaled breath condensate (EBC) pH values for healthy 
adult Croatian subjects, and to evaluate criteria for defi ning respiratory health of population providing 
normal EBC pH values in epidemiologic studies. In 109 adults without a history of lower airway symptoms 
(AS), four groups were described by narrowing the defi nition of “health” down to 1) without lower AS; 2) 
without lower and upper AS; 3) without AS, with normal FEV
1
 and bronchial normoreactivity; 4) without 
AS, with normal FEV
1
, bronchial normoreactivity, normal total IgE, and with negative skin prick test. 
Median EBC pH values did not differ between the groups (7.72, 7.73, 7.73, 7.73), but as health criteria 
got stricter, we observed a slight, nonsignifi cant increase in minimal pH values (6.95, 7.10, 7.20, 7.37). 
Median EBC pH values with interquartile range in the total sample (7.72; 7.63 to 7.76) were within the 
range previously reported by other authors. They did not differ regarding sex, smoking habit and atopic 
status, and were not associated with age, FEV
1
 or total IgE. The non-signifi cant trend in EBC pH observed 
with stricter criteria of respiratory health and atopic status indicates the need for further research on criteria 
for defi ning healthy population in a larger sample.
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As a completely non-invasive procedure, exhaled 
breath condensate (EBC) has been extensively studied 
in order to explore respiratory pathophysiology and 
its clinical relevance in the diagnosis and treatment 
of a variety of respiratory diseases, including asthma, 
chronic obstructive pulmonary disease, allergic rhinitis, 
pneumonia, adult respiratory distress syndrome, lung 
sarcoidosis, malignant lung tumours, cystic fi brosis, 
idiopathic lung fi brosis, and tuberculosis (1-3).
Many different volatile and non-volatile substances 
have been identified in EBC, such as carbon 
dioxide, ammonia, hydrogen peroxide, nucleotides, 
isoprostanes, leukotriens, nitric oxide, peptides, 
cytokines, and different ions (1, 4). There have also 
been attempts of biological monitoring of occupational 
exposure to substances, including metals and solvents 
(5-7). At present, none of these potential biomarkers 
have been suffi ciently validated for clinical use (1, 4), 
and their application in larger-scale epidemiological 
studies is not very practical since the majority of 
them can be assessed in EBC only by expensive and 
technically demanding methods. An exception may be 
pH. It is considered to be the most validated parameter 
of EBC, which can be easily and reproducibly 
measured with non-expensive equipment (1). There 
are certain limitations and unresolved questions, 
including the source of airway acidifi cation assessed 
by EBC pH, issues regarding the methodology of 
EBC collection, sample preparation and EBC pH 
measurement, as well as sensitivity and specifi city 
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of the method (8-12). Nevertheless, a number of 
studies have shown that acidifi cation caused by the 
infl ammation of the airways, like in asthma or chronic 
obstructive pulmonary disease, is refl ected in lower 
EBC pH (8).
In order to implement this method in clinical 
practice and epidemiological studies, it is necessary 
to establish reference EBC pH values in a relevant 
population, as well as to validate the method in the 
laboratory. Presently, there are EBC pH values for 
more than 600 healthy adult subjects (1, 13). At the 
same time, criteria for defi ning “health” differ between 
studies, as shown in the Table 1. A great number of 
these subjects was selected as healthy, based on data 
obtained by a questionnaire alone or in combination 
with physical examination. In other studies, health 
criteria were rather strict, and included spirometry, 
non-specifi c bronchoprovocation test, and tests for 
objective atopy markers (total and specifi c serum 
IgE, skin prick test). This raises the question of which 
criteria are the most appropriate to defi ne the health 
status for subjects who will provide normal, reference 
EBC pH values.
In this study we introduced a method for collecting 
EBC and measuring EBC pH in our laboratory, and we 
obtained preliminary EBC pH values for healthy, adult, 
smoking and non-smoking Croatian population. The 
other aim of the study was to see how EBC pH values 
vary with different criteria for defi ning respiratory 
health and atopic status in adult population.
SUBJECTS AND METHODS
Subjects and study protocol
The study involved 157 female and 43 male 
office workers from Zagreb, Croatia. All were 
volunteers, who signed an informed consent form. 
The subjects completed a questionnaire and underwent 
the following procedures: spirometry, nonspecifi c 
bronchial challenge test, EBC collection, skin prick 
test with standard inhalatory allergens, and the 
analysis of total serum IgE level. Only the subjects 
who answered that they had never had lower airway 
symptoms (25 men, 84 women) were included in the 
study. In further analysis, the defi nition of “health” 
narrowed gradually, as described on Figure 1.
Additionally, 15 subjects (of whom fi ve were 
men) reporting lower airway symptoms such as 
wheezing and/or dyspnoea with nonspecifi c bronchial 
hyperreactivity and positive skin prick test to common 
inhalatory allergens, were enrolled as positive 
control.
The study was designed in accordance with the 
Declaration of Helsinki, and was approved by the 
Institute’s Ethics Committee.
Medical history
Using a simple questionnaire, we collected medical 
history data, including age, smoking habit, lower 
airway symptoms (including episodic dry cough not 
related to common cold, wheezing, chest tightness, 
and dyspnoea), and upper airway symptoms (including 
sneezing, rhinorrhoea, nasal itching, and nasal 
obstruction not related to common cold). Smoking 
was analysed as a dichotomous variable (smoker or 
non-smoker).
Ventilatory function parameters
Forced expiratory volume in the first second 
(FEV
1
) was determined using the standard method (32) 
with spirometer Pneumoscreen II (Jaeger, Wϋrzburg, 
Germany). At least three measurements were recorded 
per subject, and the best value was used for analysis. 
FEV
1
 was expressed and analysed as a percentage 
(FEV
1
 %) of reference values (CECA II).
Nonspecifi c Bronchial Reactivity (NBR)
Nonspecific bronchial reactivity was assessed 
by means of a histamine challenge test, according 
to the procedure described by Chai et al. (33). The 
subjects inhaled doubling concentrations of histamine 
diphosphate solution (Sigma Chemical, St. Louis, 
MS) every three minutes from a DeVilbiss nebuliser 
(Model 646, DeVilbiss Health Care, Somerset, 
PA), controlled with a dosimeter (KoKo dosimeter, 
Ferraris Respiratory, Louisville, KY). The starting 
concentration of histamine diphosphate was 2 mg
mL-1, and the maximum dose used was 16 mg mL-1. 
Bronchial responsiveness was measured by recording 
the subjects’ FEV
1
 on a spirometer Pneumoscreen II 
(Jaeger, Germany) after each inhaled dose. Bronchial 
hyperreactivity was established if after the inhalation 
of  ≤8 mg mL-1 of histamine FEV
1
 dropped  ≥20 % of 
the value measured after the inhalation of the control 
solution, and further testing was stopped.
Total IgE
Total serum IgE antibodies were measured from 
venous blood samples using the enzyme-linked 
immunosorbent assay method (ELISA, IASON, Graz, 
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Table 1 Orally obtained EBC pH values in healthy adults 







healthy, no details (14) 12 CB (no) 6.15±0.16a
healthy non-smokers, no details (15) 30 ES (no) 6.30±0.30a
healthy non-smokers, non-atopics, without 
respiratory symptoms, no history of lung disease; 
normal spirometry and NBR, negative SPT (16)
15 CB (no) 6.08 (5.58 to 6.64)b
healthy, no details (spirometry was performed but 
not used as an exclusion criterion) (11)
10 CB (no) 7.24±0.24c
healthy (general health based on questionnaire) 
(17)
21 RT (no) 6.17, 5.96 to 6.31d




7 ES (no) 7.29±0.25a
16 ES (argon) 8.26±0.20a
healthy non-smokers, without acute or chronic 
respiratory symptoms or disease, no history of 




6.05±0.09a, 6.12 (5.25 to 6.82)b
6.01±0.05a, 6.01 (5.25 to 6.41)b
RT (argon)
7.50±0.13a, 7.72 (5.26 to 8.13)b
7.59±0.09a, 7.72 (6.44 to 8.12)b
healthy non-smokers and smokers, no history 
of asthma, allergic rhinitis, hay fever, or atopic 
dermatitis (20)
270
RT (no) 6.17, 5.50 to 6.78d
RT (argon) 8.09, 7.41 to 8.23d
subjects without respiratory symptoms and history 
of asthma (21)
19 CB (argon) 7.65±0.20e
healthy non-smokers, no history of allergy; normal 
spirometry and NBR, negative SPT (22)
10 CB (argon) 7.47±0.12, 7.49±0.10a
healthy non-smokers, no details (23) 12 ES (argon) 7.46±0.48a
healthy non-smokers, no history of significant 
chronic respiratory disease (24)
76 RT (argon) 7.70±0.49a
subjects undergoing elective surgery, no history of 
chronic respiratory disease (25)
32 RT (argon) 7.90±0.23a
healthy non-smokers, no details (25) 10 RT (argon) 7.90±0.30a, 7.80±0.30a
healthy, non-smokers, without respiratory tract 
infection within the last 4 weeks (26)
12 ES (argon) 7.61 (7.52 to 7.70)f
healthy non-smokers, without pulmonary disease, 
non-atopics (negative SPT, not elevated total and 
specifi c IgE), normal spirometry, NBR and blood 
gas analysis (27)
15 ES (argon) 7.85±0.14a
no history of lung disease, non-atopics (negative 
SPT), normal spirometry and NBR (28)
7 ES (argon) 7.90±0.10c
healthy, without respiratory disorders, any acute or 
chronic systemic illness, and physician-diagnosed 
gastric disease (13)
404h RT (argon)
8.00, 7.80 to 8.10d
 (4.50 to 8.40)g
healthy non-smokers, without physician’s diagnosis 
of asthma, without respiratory symptoms; normal 
spirometry (FEV
1
), negative bronchodilator test 
and SPT (29)
30
ES (argon) 7.55 (6.88 to 7.90)d
RT (argon) 7.54 (7.09 to 7.93)d
healthy non-smokers with normal weight, without 
heart diseases, lung diseases and allergies (medical 
history and examination) (30)
15 RT (nitrogen) 8.20±0.13a
healthy non-smokers, no history of respiratory 
disease; normal spirometry, normal NBR (31)
16 ES (argon) 6.72 (6.38 to 6.98)d
a mean ± SD; b median (range); c mean ± SEM; d median, interquartile range; e geometric mean ± SEM; f mean (95 % confi dence 
interval); g range; h including 226 subjects older than 20 years; EBC – exhaled breath condensate; NAD – no abnormalities 
detected; NBR – non-specifi c bronchial reactivity; SPT – skin prick test; FEV
1
 – forced expiratory volume in the 1st second; CB 
– custom built EBC sampling device; ES – EcoScreen ; RT – RTube
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Austria) (34). IgE levels were expressed in kIU L-1 and 
values <150 kIU L-1 were considered normal.
Skin prick testing
Skin prick testing (SPT) was performed using 
a standard method (35) with a panel of common 
commercial inhalatory allergens: grass pollen 
mixture, birch, hazel, weed (Ambrosia elatior, 
Artemisia vulgaris) pollens, mites Dermatophagoides 
pteronyssinus, Dermatophagoides farinae, and 
Lepidoglyphus destructor, cat, dog, and moulds 
Cladosporium herbarum and Alternaria alternata 
(Allergopharma, Reinbeck, Germany). SPT included 
testing with positive control solution (10 mg mL-1 of 
histamine hydrochloride) and negative control solution 
(buffer solution). Skin reaction (wheal) was evaluated 
after 15 min. The mean skin reaction (mean wheal 
diameter) was calculated according to the formula 
(D+d)/2, where D represents the largest longitudinal 
diameter and d its midpoint orthogonal diameter in 
millimetres. For statistical evaluation, the difference 
between mean skin reaction to each allergen and 
negative control solution was used as a parameter of 
SPT reactivity. The results of SPT were considered 
positive (positive SPT) when the mean wheal diameter 
was larger than the negative control for more than 
3 mm to at least one tested allergen.
Atopy status was defi ned as the presence of both 
elevated total IgE and positive SPT to at least one 
tested allergen.
EBC collection and pH measurement
All subjects were asked to fast for at least 12 h 
and refrain from smoking at least one hour before 
sampling. For the sampling, all subjects wore nose 
clips. Each subject provided a single EBC sample, 
breathing tidally into a commercial condenser (Eco 
Screen; Jaeger, Germany) for 15 min through a 
mouthpiece and a two-way non-rebreathing valve 
that also prevented saliva contamination due to 
integrated saliva trap. The condensate was collected 
into a Tefl on-coated tube, which was disinfected and 
rinsed with tap water and wiped before sampling. 
After collection, the samples were frozen at -20 °C 
until analysis.
The samples were allowed to thaw to room 
temperature and were left exposed to ambient air until 
pH was stable (for three hours on average). pH was 
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Exclusion of subjects with upper airway 
symptoms (N=51)
Subjects without lower or upper airway symptoms (N=58) 
Exclusion of subjects with FEV1<80 % of predicted (N=0) 
Subjects without lower or upper airway symptoms and with normal FEV1 (N=58) 
Subjects without lower or upper airway symptoms, with normal FEV1 and NBR (N=53) 
Exclusion of subjects with bronchial hyperreactivity (N=5) 
Exclusion of subjects with elevated IgE and positive SPT 
(N=13), plus one female subject in which IgE level was not 
analysed (lost sample)  
Subjects without lower or upper airway symptoms, with normal 
FEV1, NBR and IgE and with negative SPT (N=39) 
Subjects without lower airway symptoms (N=109) 
Figure 1  The steps in narrowing the defi nition of “health” with stricter criteria of respiratory health and atopic status
FEV
1
 – forced expiratory volume in the 1st second ; NBR – non-specifi c bronchial reactivity; SPT – skin prick test to standard 
inhalatory allergens
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measured using a Mettler pH meter (standard glass 
electrode-MP 220 Toledo, accuracy ±0,01) that had 
been calibrated with standard buffers (Mettler Toledo) 
at two points (pH 7.00 and pH 4.01).
Statistical analysis
The results are presented as mean values with 
standard deviations (age, FEV
1
) or as medians with 
range (smoking index, total IgE, EBC pH) and 
interquartile range (EBC pH). Differences between 
groups (e.g. men and women, smokers and non-
smokers, subject with and without upper airway 
symptoms) were tested with Student’s t-test (age, 
FEV
1
), Mann-Whitney U test (smoking index, 
EBC pH, total IgE), or Fisher’s exact test (number 
of smokers, prevalence of respiratory symptoms, 
bronchial hyperreactivity, elevated IgE and positive 
SPT). Possible associations between EBC pH and 
age and FEV
1
 and total IgE were analysed with 
Spearman’s correlation. Difference in EBC pH was 
tested between four overlapping groups defi ned as 
healthy according to criteria shown in Figure 1. The 
healthy groups were analysed as independent samples 
using the Kruskal-Wallis analysis of variance. EBC 
pH of each healthy group was also compared with 
positive control group using the Mann-Whitney U test. 
A P value of less than 0.05 was considered statistically 
signifi cant in all analyses. Statistical analysis was 
performed using statistical software Stata/SE 10.0 for 
Windows (StatCorp LP, TX, USA).
RESULTS AND DISCUSSION
Table 2 shows the data about the age, smoking, 
respiratory parameters, and the prevalence of upper 
airway symptoms and positive objective atopy 
markers in subjects without a history of lower airway 
symptoms. The only difference found between men 
and women was a signifi cantly higher prevalence 
of positive SPT and positive both objective atopy 
markers in men. The prevalence of positive SPT was 
more than two times higher, and the prevalence of 
positive both atopy markers seven times higher in men 
than in women. Only one female subject had FEV
1
 
lower than 80 % of the predicted value. Her FEV
1
 was 
78.5 %, and EBC pH 7.78.
Table 3 shows the profile of positive control 
subjects. Male to female ratio (approximately 1:3; 
Pearson χ2=0.78, P=0.355), the number of smokers 
(Pearson χ2=0.79, P=0.550), as well as age (t=1.502, 
P=0.136), did not differ signifi cantly between subjects 
without lower airway symptoms and positive controls. 
Due to a very low number of smokers (three subjects) 
in the positive control group, smoking was not further 
analysed as a variable in this group. As expected, FEV
1
 
was lower in positive controls (t=-2.4673, P=0.015) 
and IgE levels were higher (z=4.082, P<0.0001) 
than in subjects without lower airway symptoms. In 
addition, the prevalence of upper airway symptoms 
was signifi cantly higher in positive controls (14 out 










































Total (109) 42.2 ± 9.0 34 (31.2) 200, 5 to 660 51 (46.8) 105.5 ± 11.8 13 (12.2) 24.3, 0 to1000 16 (14.7) 32 (29.4) 10 (9.3)
Men (25) 43.4 ± 9.2 5 (20.0) 240, 10 to 600 9 (36.0) 106.3 ± 11.6 1 (4.0) 40.5, 0 to 000 7 (28.0) 13 (52.0) 7 (28.0)























 P= 0.000 
a In 2 women NBR test was not performed due to contraindications; b Serum sample from one subject was lost; c One woman 
had FEV
1
 below 80 % (78.5 %); EBC – exhaled breath condensate; FEV
1
 – forced expiratory volume in the 1st second ; NBR 
– non-specifi c bronchial reactivity; SPT – skin prick test to standard inhalatory allergens; Differences between men and women 
were tested by Student’s t-test (age, FEV1), Mann-Whitney U test (smoking index, total IgE), or by Fisher’s exact test (number 
of smokers, upper airway symptoms, bronchial hyperreactivity, elevated IgE, positive SPT, and elevated IgE + positive SPT). 
A P value of less than 0.05 was considered statistically signifi cant. 
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of 15 subjects; Pearson χ2=11.45, Fisher’s exact 
P=0.001).
Table 4 shows median EBC pH values with 
interquartile range and minimum and maximum values 
for subjects without lower airway symptoms. They 
are within the range of values previously reported by 
other authors (Table 1). Table 4 also gives the values 
for positive controls.
In subjects without lower airway symptoms 
EBC pH was not associated with age (Spearman’s 
r=0.049, P=0.611), FEV
1
 (r=0.024, P=0.806), or IgE 
(r=-0.148, P=0.126). There were no differences in 
EBC pH between men (median, 7.73, interquartile 
range, 7.63 to 7.77) and women (7.71, 7.64 to 7.76; 
z=0.126; P=0.900), smokers (7.69, 7.48 to 7.77) and 
non-smokers (7.73, 7.65 to 7.75; z=0.809; P=0.419), 
subject without upper airway symptoms (7.73, 7.66 
to 7.76) and subjects with upper airway symptoms 
(7.70, 7.53 to 7.76; z=1.307, P=0.191), subjects with 
bronchial normoreactivity (7.72, 7.63 to 7.76) and 
those with bronchial hyperreactivity (7.69, 7.64 to 
7.75; z=0.377, P=0.706), and between atopics (7.76, 
7.63 to 7.87) and non-atopics (7.71, 7.63 to 7.76; 
z=-1.221; P=0.222). The correlations between EBC 
pH and age and FEV
1
, and IgE were not signifi cant 
in positive controls as well (r=-0.1530, P=0.586; 
r=0.2484, P=0.372; r=-0.3753, P=0.168, respectively). 
Just like subjects without lower airway symptoms, 
positive control men and women did not differ in 
EBC pH (z =-0.919, P=0.358). It has repeatedly been 
shown by other authors that age, sex, and smoking 
have no effect on EBC pH (13, 17, 19, 20, 24). On 
the other hand, there are studies showing acute effects 







 and interleukin-6 
levels (36-39), and EBC pH (40). The intensity of 
current smoking (number of cigarette packs smoked 
per day now) negatively correlated with EBC pH (40). 
However, it seems that active smoking does not affect 
EBC pH in subjects without a respiratory disease who 
refrain from smoking at least one hour before EBC 
collection (17, 24). The situation could be different in 
asthma patients, in whom smoking is associated with 
lower EBC pH than in non-smoking asthmatics (41). 
In our subjects with lower airway symptoms (positive 
control), however, the number of smokers was too low 
to allow statistical analysis, as mentioned above. To 
avoid possible acute effect of smoking on EBC pH, 
all subjects that entered the study did not smoke for 
at least one hour before EBC sampling.
EBC is believed to contain droplets of fl uid lining 
the pulmonary surfaces (epithelial lining fl uid), but 
their source may just as well be the upper respiratory 
tract and the upper gastrointestinal tract (42). In light 
of the concept of “united airways”, it is also possible 
that upper and lower airway disorders co-exist, and 
that the progression of atopic disease that manifests 
itself as allergic rhinitis can lead to acidifi cation of 
the lower airways before asthma symptoms appear 
(43). This is supported by the fi ndings that children 
with allergic rhinitis have lower EBC pH than healthy 
children, even in the absence of clinical signs of 
infl ammation in the lower airways (43, 44) EBC pH 
in non-allergic upper respiratory disorders has not 
been studied so far. We did not observe an effect of 
the presence of upper airway symptoms on EBC pH 
in adult subjects without lower airway symptoms. 
Since these subjects were mainly non-atopics (99 out 
of 109), we could not establish a difference between 
the effects of atopic and non-atopic upper airway 
symptoms on EBC pH.
The lack of association between FEV
1
 or non-
specifi c bronchial reactivity and EBC pH in our study 
is no surprise as it enrolled only healthy subjects. A 
correlation between EBC pH and FEV
1
 was observed 
in children with asthma (43) and in adult patients 
with asthma, chronic obstructive pulmonary disease 
(COPD), or bronchiectasis, but not in healthy control 
subjects (non-atopics with normal lung function and 
normal bronchial reactivity) (22). Data on EBC pH and 
non-specifi c bronchial reactivity are scarce. A positive 
trend (although not statistically significant) was 
found between EBC pH and non-specifi c bronchial 
reactivity in children with wheezing (45), but data 
for a population without airway symptoms are not 
available in literature.
As pointed out by Paget-Brown et al. (13) and 
Koutsokera et al. (1), there are plenty of studies of 
EBC pH which include healthy subjects, primarily 
to compare them with subjects with respiratory 
disease. Table 1 summarises the pH values of orally 
obtained EBC samples in healthy adults from different 
published studies. Between these studies, “health” 
criteria differ a lot. Differences are also substantial in 
the use of EBC sampling device, sampling procedure 
(e.g. duration), storage of samples (e.g. temperature 
and duration), sample preparation (native or treated 
with inert gas), and pH measurement (standard pH 
electrode, microelectrode, blood gas analyzer). An 
extensive study by Paget-Brown et al. (13), for 
example, included 404 healthy subjects of both 
sexes, with 226 subjects older than 20 years. The 
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Total (15) 46.0 ± 10.9 3 (20.0) 75, 35 to 240 14 (93.3) 96.8 ± 18.8 180.6, 15.5 to 795.2 9 (60.0)
Men (5) 46.6 ± 15.3 1 (20.0) 35 5 (100.0) 89.8 ± 21.8 333.2, 180.6 to 795.2 5 (100.0)
Women (10) 45.7 ±   8.9 2 (20.0) 158, 75 to 240 9 (90.0) 100.3 ± 17.4 74.4, 15.5 to 418.5 4 (40.0)
*Positive controls were subjects with lower airway symptoms, bronchial hyperreactivity, and positive skin prick test to common 
inhalatory allergens
EBC – exhaled breath condensate; FEV
1
 – forced expiratory volume in the 1st second
Table 4 EBC pH in subjects with different criteria for respiratory health and atopy, and in positive controls
N
pH Comparison with positive 






Without lower airway symptoms
Men 25 7.67±0.22 7.73 7.20 to 8.26 7.63 to 7.77
Women 84 7.67±0.20 7.71 6.95 to 8.10 7.64 to 7.76
Total 109 7.67±0.21 7.72 6.95 to 8.26 7.63 to 7.76 z=-2.343, P=0.0191
Without lower and upper airway symptoms
Men 16 7.71±0.15 7.75 7.20 to 7.87 7.68 to 7.77
Women 42 7.68±0.17 7.73 7.10 to 7.96 7.66 to 7.75
Total 58 7.69±0.16 7.73 7.10 to 7.96 7.66 to 7.76 z=-2.756, P=0.0059
Without airway symptoms, with normal FEV
1
 and NBR
Men 15 7.71±0.15 7.75 7.20 to 7.87 7.66 to 7.77
Women 38 7.69±0.14 7.73 7.32 to 7.96 7.66 to 7.75
Total 53 7.69±0.14 7.73 7.20 to 7.96 7.66 to 7.76 z=-2.785, P=0.0054
Without airway symptoms, with normal FEV
1
, NBR and total IgE, and with negative SPT
Men 7 7.71±0.06 7.70 7.64 to 7.78 7.66 to 7.77
Women 32 7.70±0.14 7.73 7.37 to 7.96 7.67 to 7.77
Total 39 7.70±0.13 7.73 7.37 to 7.96 7.66 to 7.77 z=-2.771, P=0.0056
Positive 
controls
Men 5 7.59±0.37 7.45 7.30 to 8.22 7.39 to 7.60
Women 10 7.59±0.14 7.60 7.30 to 7.76 7.50 to 7.73
Total 15 7.59±0.23 7.56 7.30 to 8.22 7.45 to 7.73
EBC – exhaled breath condensate; P
25
 – 25th percentile; P
75
 – 75th percentile; FEV
1
 – forced expiratory volume in the 1st second; 
NBR – non-specifi c bronchial reactivity; SPT – skin prick test to standard inhalatory allergens; Positive control – subjects 
reporting wheezing and/or dyspnoea with positive SPT and bronchial hyperreactivity
Median EBC pH values did not differ between the healthy groups (Kruskal-Wallis analysis of variance, P=0.817). The difference 
between healthy groups and positive control was tested by Mann-Whitney U test.
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Figure 2  Box plots of EBC pH distribution in the four health 
categories and in positive control
0 – Positive control (subjects reporting wheezing and/or 
dyspnoea with positive SPT and bronchial hyperreactivity; 
N=15); 1 – Subjects without lower airway symptoms (N=109); 
2 – Subjects without lower and upper airway symptoms 
(N=58); 3 – Subjects without airway symptoms, with normal 
FEV
1
 and NBR (N=53); 4 – Subjects without airway symptoms, 
with normal FEV
1
, NBR and total IgE, and with negative SPT 
(N=39); EBC – exhaled breath condensate; FEV
1
 – forced 
expiratory volume in the 1st second; NBR – non-specifi c bron-
chial reactivity; SPT – skin prick test to standard inhalatory 
allergens
Data are presented as medians with interquartile ranges, 
adjacent values, and minimal and maximal values.
health status was self-described by volunteers, and 
certain exclusion criteria were introduced to refi ne the 
selection. Excluded were smoking subjects, as well 
as those who reported chronic upper or lower airway 
symptoms, or symptoms related to viral respiratory 
tract infection (common cold). Similarly, the study 
of Vaughan et al. (24) on factors relevant to EBC 
pH monitoring involved 76 healthy non-smoking 
subjects whose respiratory health was defi ned as the 
absence of a “history of signifi cant chronic respiratory 
disease”. The most recent study by Hauswirth et al. 
(20) included 270 healthy subjects of African ancestry 
whose health status was based on self-reported 
absence of a history of asthma, allergic rhinitis, hay 
fever, or atopic dermatitis. Studies in which respiratory 
and/or atopic status was more extensively evaluated 
usually involved a small number of subjects who 
served as a controls (16, 22, 27-29, 31). Which are 
the most appropriate health criteria for the selection of 
reliable and representative healthy control providing 
normal EBC pH values is still an unresolved issue 
that may be of particular interest for epidemiologic 
research. We defi ned our healthy subjects according 
to different criteria based on subjective and objective 
respiratory and atopic parameters. Four overlapping 
groups were described by narrowing the defi nition 
of “health” in four steps: in the 1st step we excluded 
subjects with lower airway symptoms (also the criteria 
for enrolment in the study); in the 2nd, from the group 
formed in the 1st step we excluded subjects with upper 
airway symptoms; in the 3rd, from the group formed 
in the 2nd step we excluded subjects with bronchial 
hyperreactivity and FEV
1
<80 %, and in the 4th step, 
from the group formed in previous step we excluded 
atopic subjects (with elevated IgE and positive SPT) 
(Figure 1, Table 4). Median values (7.72, 7.73, 7.73, 
and 7.73 for each respective step) and interquartile 
ranges were quite similar between the groups, and 
they showed no difference in EBC pH (Kruskal-Wallis 
ANOVA: χ2=0.934, P=0.817). However, the range of 
values narrowed with stricter criteria, and we observed 
a slight increase in minimal (6.95, 7.10, 7.20, and 
7.37, respectively) and mean pH values (7.67, 7.69, 
7.69, and 7.70, respectively) (Figure 2). This, albeit 
non-signifi cant, trend indicates the need for further 
research on a larger sample. Since our sample size was 
limited, especially regarding healthy groups meeting 
stricter health criteria, any fi rm conclusion would be 
premature.
The pH values obtained from our participants are 
closer to values measured in samples after deaeration/
decarbonation, although we did not treat the samples 
with inert gas (argon or nitrogen) to stabilise the pH. 
In general, literature describes three main approaches 
to EBC pH measurement: 1) in native samples, fresh or 
after defrosting; 2) after treating the samples with inert 
gas (bubbling or overlaying); and 3) at a standard CO
2
 
level of the sample (1). The last method is proposed 
to be the most accurate (10). In our study, the samples 
were left at room temperature to permit gas exchange 
(primarily CO
2
 as a major EBC volatile component) 
with ambient air. We are aware that this procedure 
probably eliminates less CO
2
 from the sample then 
does deaeration/decarbonation with inert gas. Also, a 
greater variation in CO
2
 content (and consequently in 
pH value) is to be expected in our samples compared 
to dearated/decarbonated samples, and especially to 
samples in which pH was measured at a standard CO
2
 
level of the sample. Since our method has not yet been 
validated, in order to see whether it could discriminate 
between subjects with and without inflammatory 
changes in the airways, we introduced a positive 
control, i.e. subjects reporting lower airway symptoms 
typical for asthma (wheezing and/or dyspnoea) with 
positive SPT and bronchial hyperreactivity. We found 
that each healthy group had a signifi cantly (0.16 to 
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0.17 units) higher EBC pH than positive control, 
indicating that the described method is able to detect 
airway acidifi cation. 
CONCLUSION
This study brings the fi rst results on EBC pH 
in adult Croatian population without respiratory 
disorders. EBC pH values seem not to be affected 
by age, sex, smoking, upper airway symptoms, non-
specifi c bronchial reactivity, or atopy. The established 
normal EBC pH range in our study is mildly alkaline 
and tight, and is comparable with data published 
in literature. Our data do not suggest that stricter 
health criteria for defi ning normal population bring 
an advantage for epidemiologic studies of EBC pH. 
Exclusion of subjects with respiratory symptoms and 
atopy did however show a slight trend toward more 
alkaline pH. This calls for further research in a larger 
number of subjects.
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Sažetak
pH KONDENZATA IZDAHA U ODRASLE POPULACIJE HRVATSKE BEZ DIŠNIH POREMEĆAJA 
– KOLIKO ZDRAVA TREBA BITI POPULACIJA U KOJOJ SE UTVRĐUJU NORMATIVNE 
VRIJEDNOSTI?
Ciljevi preliminarnog istraživanja bili su izmjeriti pH-vrijednosti kondenzata izdaha (pH KI) odraslih 
stanovnika Hrvatske bez dišnih poremećaja te utvrditi kriterije potrebne za defi niranje zdravlja dišnog 
sustava populacije u kojoj se planiraju utvrditi normalne pH-vrijednosti KI-a. U uzorku od 109 odraslih 
osoba bez tegoba od strane donjih dišnih putova, sužavajući defi niciju “zdravlja”, opisane su 4 skupine 
ispitanika: 1) bez donjih dišnih simptoma (DS); 2) bez gornjih i donjih DS; 3) bez DS i hiperreaktivnosti 
bronha s normalnim FEV
1
; 4) bez DS i hiperreaktivnosti bronha s normalnim FEV
1
, ukupnim IgE i s 
negativnim prick testom. Medijani pH-vrijednosti nisu se razlikovali između skupina (7,72; 7,73; 7,73; 
7,73), ali uvođenjem sve strožih kriterija zdravlja uočen je blag, iako nesignifi kantan, porast minimalnih 
pH-vrijednosti KI-a (6,95; 7,10; 7,20; 7,37). Medijan pH KI s interkvartilnim rasponom u ukupnom uzorku 
(7,72; 7,63 do 7,76) bio je unutar raspona vrijednosti izmjerenih u istraživanjima drugih autora. Na pH 
KI nisu utjecali spol, navika pušenja i atopijski status i nije bio povezan s dobi, vrijednostima FEV
1
 ili 
ukupnim IgE. Uočeni nesignifi kantni trend porasta pH KI nakon uvođenja strožih zdravstvenih kriterija 
sugerira potrebu daljnjih istraživanja kriterija za defi niranje zdravlja dišnog sustava na većem uzorku.
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